Примери за използване на Products for human use на Английски и техните преводи на Български
{-}
-
Medicine
-
Colloquial
-
Official
-
Ecclesiastic
-
Ecclesiastic
-
Computer
As regards medicinal products for human use, Article 98(3) of Directive 2001/83/EC shall apply to medicinal products authorised under this Regulation.
answers regarding the implementation of the rules on the safety features for medicinal products for human use.
answers' regarding the implementation of the rules on the safety features for medicinal products for human use.
An updated Risk Management Plan should be provided as per the CHMP guideline on Risk Management Systems for medicinal products for human use.
clinical trials regulation and the locally registered medicinal products for human use.
An updated Risk Management Plan should be provided as per the CHMP guideline on Risk Management Systems for medicinal products for human use.
An updated Risk Management Plan should be provided as per the CHMP guideline on Risk Management Systems for medicinal products for human use.
Of 6 November 2001 on the Community code relating to medicinal products for human use.
GDP certification demonstrates that GEFCO fulfils the requirements of the European Commission Guidelines on Good Distribution Practice of Pharmaceutical Products for human use, and is valid for three years.
An updated Risk Management Plan should be provided as per the CHMP guideline on Risk Management Systems for medicinal products for human use.
Directive 89/105/EEC, relating to the transparency of measures regulating the prices of medicinal products for human use and their inclusion in the scope of public health insurance systems[1989] OJ L40/8.
As per the CHMP Guideline on Risk Management Systems for medicinal products for human use, the updated RMP should be submitted at the same time as the next Periodic Safety Update Report(PSUR).
COUNCIL DIRECTIVE of 21 December 1988 relating to the transparency of measures regulating the pricing of medicinal products for human use and their inclusion in the scope of national health insurance systems.
On 22 October 2015, the European Medicines Agency(EMA) Committee for Medicinal Products for Human Use(CHMP) adopted a positive opinion,
Council Directive 89/105/EEC relating to the transparency of measures regulating the pricing of medicinal products for human use and their inclusion within the scope of national health insurance systems.
Directive 89/105/CEE CEE relating“to the transparency of measures regulating the prices of medicinal products for human use and their inclusion in the scope of public health insurance systems”.
As per the CHMP Guideline on Risk Management Systems for medicinal products for human use, any updated RMP should be submitted at the same time as the following Periodic Safety Update Report(PSUR).
As per the CHMP Guideline on Risk Management Systems for medicinal products for human use, the updated RMP should be submitted at the same time as the next Periodic Safety Update Report(PSUR).
As per the CHMP Guideline on Risk Management Systems for medicinal products for human use, the updated RMP should be submitted at the same time as the next Periodic Safety Update Report(PSUR).
The Committee for Medicinal products for Human Use(CHMP) decided that Targretin's benefits are greater than its risks for the treatment of the skin manifestations of advanced stage cutaneous T-cell lymphoma patients refractory to at least one systemic treatment.